Galactosidase Enzyme Fragment Complementation as a High-Throughput Screening Protease Technology

Abstract

The authors describe a homogeneous, high-throughput screening (HTS) assay for measuring protease activity and detection of inhibitors. The assay comprises a cyclic β-galactosidase (β-gal) enzyme donor peptide (ED) containing a protease-selective cleavage sequence. Alone, the cyclic peptide is inactive, but when linearized following protease cleavage, ED complements with β-gal enzyme acceptor forming active β-gal enzyme. This then catalyzes the formation of either fluorescent or chemiluminescent products, with β-gal turnover providing a highly amplified signal, and thus an assay technology of high sensitivity. To demonstrate the utility of the technology, an EFC assay was developed to measure the activity of 2, caspase 3 and β-secretase. Using a cyclic ED containing the caspase 3 substrate sequence, DEVD, the EFC assay signal was linear with respect to caspase 3 concentration. The assay was very sensitive, being able to detect activity at low picogram amounts of caspase 3. For the β-secretase (BACE) EFC assay, a cyclic ED containing the Swedish mutant cleavage site of amyloid precursor protein (APP), SEVNLDAEFK, was used. In a similar fashion to the caspase 3 assay, the signal induced by BACE activity was linear with respect to enzyme concentration and was highly sensitive, being able to detect nanogram quantities of BACE. The assay was also more sensitive than a commercially available FRET-based assay of BACE activity. It is concluded that the EFC protease assay is a simple, flexible, and sensitive technology for HTS of proteases.

Keywords

enzyme fragment complementation β galactosidase protease assays caspase 3 β secretase BACE

References

1. Andersen H , Greenberg D , Fujikawa K , Xu W , Chung D , Earl D : Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A 1999;96:11189-11193.

2. Hook V : Proteolytic and Cellular Mechanisms of Prohormone and Proprotein Processing. Austin, TX: Landes, 1998.

3. Xia L , Justine K , Heike L , Zhen Qiang L , Lipyansky A , Breuil V , et al : Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem 1999;380:679-687.

4. Lam P , Jadhav P , Eyermann C , Hodge C , Ru Y , Bacheler L , et al : Rational design of potent, bioavailable nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994:263:380-384.

5. Vocero-Akbani A , van der Heyden N , Lissy N , Lee R , Dowdy S : Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nature Med 1999;5:29-33.

6. Patrick A , Potts K : Protease inhibitors as antiviral agents. Clin Microbiol Rev 1998;11:614-627.

7. Sloane B , Honn K : Cysteine proteinases and metastasis. Cancer Metasis Rev 1984:3:249-263.

8. Ona V , Vonsattel J-P , Andrews L , Khan S , Chung W , Frey A , et al : Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 1999;399:263-267.

9. Mignatti P , Rifkin D : Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-195.

10.

10. Wolf B , Green D : Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1999;274:20049-20025.

11.

11. Wellington C , Singaraja R , Ellerby L , Savill J , Roy S , Blair B , et al : Inhibiting caspase cleavage of Huntington reduces toxicity and aggregate formation in neuronal and non-neuronal cells. J Biol Chem 2000;275:19831-19838.

12.

12. Vassar R , Bennett B , Babu-Khan S , Kahn S , Mendiaz E , Denis P , et al : β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-741.

13.

13. Leung D , Abbenante G , Fairlie DP : Protease inhibitors: current status and future prospects. J Med Chem 2000;43:305-341.

14.

14. Stennicke H , Salvesen G : Caspase assays. Meth Enzymol 2000;322:91-100.

15.

15. Skovronsky D , Pijak D , Doms R : A distinct ER/IC gamma secretase competes with the proteasome for cleavage of APP. Biochemistry 2000;39:810-817.

16.

16. Mahajan N , Harrison-Shostak D , Michaux J , Herman B : Novel mutant green fluorescent protein protease substrates reveal the activation of specific caspases during apoptosis. Chem Biol 1999;6:401-409.

17.

17. George J , Teear M , Norey C , Burns D : Evaluation of an imaging platform during the development of FRET protease assay. J Biomol Screen 2003;8:72-80.

18.

18. Eglen R : Technology review: enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev Technol 2002;1:97-104.

19.

19. Eglen R , Singh R : β galactosidase enzyme fragment complementation as a novel technology for high throughput screening. Combinat Chem HTS 2003;6:381-387.

20.

20. Golla R , Seethala R : A homogenous enzyme fragment complementation cAMP screen for GPCR agonists. J Biomol Screen 2002;7:515-525.

21.

21. Vainshtein I , Silveria S , Kaul P , Rouhani R , Eglen R , Wang J : A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP™). J Biomol Screen 2002;7:497-504.

22.

22. Gruninger-Leitch F , Schlatter D , Kung E , Nebock E , Dobeli H : Substrate and inhibitor profile of BACE and comparison with other mammalian aspartic proteases. J Biol Chem 2002;277:4687-4693.

23.

23. Gruninger-Leitch F , Berndt P , Langen H , Nelboeck P , Dobeli H : Identification of β secretase-like activity using a mass spectrometry-based assay system. Nature Biotech 2000;18:66-70.

24.

24. Fmoc solid phase peptide synthesis: a practical approach. Chan WC , White PD (eds). New York: Oxford University Press, 2000:277-291.

25.

25. Kaiser E , Colescott R , Cook P : Color test for diction of free terminal amino groups in the solid phase synthesis of peptides. Anal Biochem 1970;34:595-598.

26.

26. Blake J , Li C : Adrenocortin 47. Synthesis and biological activity of adrenocorticotropic peptides modified at the tryptophan position. Int J Peptides 1975;7:495-506.

27.

27. Radisky E , King D , Kwan G , Koshland D : The role of the protein core in the inhibitory power of the classic serine protease inhibitor, Chymotrypsin Inhibitor 2. Biochem 2003;42:6484-6492.

28.

28. Fairlei D , Tyndall J , Reid R , Wong A , Abbenante G , Scanlon M , et al : Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing. J Med Chem 2000;43:1271-1281.

29.

29. Villemure M , Fourniere A , Gauthier D , Rabah N , Wilkes B , Lazure C : Barley serine protease inhibitor 2-derived cyclic peptides as potent and selective inhibitors of convertases PC1/3 and Furin. Biochem 2003;42:9659-9668.